期刊文献+

重症肌无力的诊断与治疗 被引量:12

Diagnosis and treatment of myasthenia gravis
原文传递
导出
摘要 重症肌无力主要是由乙酰胆碱受体抗体介导的获得性神经肌肉接头传递障碍的自身免疫性疾病,临床表现为全身骨骼肌收缩无力。疾病早期眼外肌受累可出现眼睑下垂、复视等症状,易被误诊为眼科疾病,当出现咽喉肌、四肢肌无力时更需与多种疾病鉴别,临床存在一定程度的漏诊、误诊。文中概述了重症肌无力的流行病学、病因及发病机制、临床表现、分型、辅助检查、诊断及鉴别诊断、治疗进展等内容,供临床及神经专科医生参考。 Myasthenia gravis(MG)is mainly acetylcholine receptor antibody-mediated acquired autoimmune disease that affects the postsynaptic membrane at the neuromuscular junction.The predominant manifestation is muscle weakness.Extraocular muscles are frequently affected in the early stage of disease with typical symptoms of intermittent drooping of the upper eyelid(ptosis)and double vision(diplopia),which is easy to be misdiagnosed as an ophthalmic disease.When the weakness of the face,bulbar,neck and limb muscles occur,it needs to be differentiated from a variety of diseases.Other clinical disorders can present in a similar fashion and may be mistakenly labeled as MG.This paper summarizes the epidemiology,etiology,pathogenesis,clinical manifestations,classification,auxiliary examination,diagnosis,differential diagnosis,and treatment progress of MG,which can be used as a reference for clinicians and neurologists.
作者 李柱一 常婷 Li Zhuyi;Chang Ting(Department of Neurology,Tangdu Hospital,the Second Affiliated Hospital of People′s Liberation Army Air Force Military Medical University,Xi′an 710038,China)
出处 《中华神经科杂志》 CAS CSCD 北大核心 2022年第3期238-247,共10页 Chinese Journal of Neurology
基金 陕西省重点研发计划-重点产业创新链(2021ZDLSF02-01) 唐都医院临床研究重大项目(2021LCYJ002)。
关键词 重症肌无力 诊断 治疗 Myasthenia gravis Diagnosis Treatment
  • 相关文献

参考文献2

二级参考文献16

  • 1彭丹涛,许贤豪,佘子瑜.新斯的明试验改良结果判定法研究[J].中国神经免疫学和神经病学杂志,2007,14(1):1-3. 被引量:26
  • 2Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and tuture[J]. J Clin Invest, 2006, 116(11): 2843-2854.
  • 3Kerry E, Elsais A, Argov Z, et al. NE. EFNS/ENS Guidelines for the treatment of ocular myasthenia [ J ]. Eur J Neurol, 2014, 21(5) : 687-693.
  • 4Luehanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence basel[ J ]. Curr Opin Neurol, 2008, 21 ( 1 ) : 8-15.
  • 5Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment[ J]. J Neurol Sci, 2007, 261 (1-2) : 127-133.
  • 6Meriggioli MN, Sanders DB. Autoimmune myasthcnia gravis: emerging clinical and biological heterogeneity[ J]. Lancet Neurol, 2009, 8(5) : 475-490.
  • 7Meyer DM, Herbert MA, Sobhani NC, et al. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches[ J]. Ann Thorac Surg, 2009, 87(2) : 385-390.
  • 8Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders [ J ]. Eur J Neurol, 2010, 17(7) : 893-902.
  • 9Jani-Acsadi A, Lisak RP. Myasthenia gravis [ J ]. Curr Treat Options Neurol, 2010, 12 ( 3 ) : 231-243.
  • 10Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders [ J ].Ther Adv Neurol Disord, 2010, 3(2): 93-105.

共引文献511

同被引文献117

引证文献12

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部